Todd Harris and Daniel Bensen. Tyra
RA Capital, Canaan help infuse $50M into Alta-incubated biotech battling acquired resistance to TKIs
Since Gleevec was approved in 2001, over 40 other tyrosine kinase inhibitors have come onto the market to treat various types of cancer. But with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
